One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Clinical Validation of a Capillary Blood Home-Based Self-Sampling Technique for Monitoring of Infliximab, Vedolizumab, and C-Reactive Protein Concentrations in Patients With Inflammatory Bowel DiseaseÂ
Antonius T Otten, MD, Hedwig H van der Meulen, Maurice Steenhuis, PhD, Floris C Loeff, PhD, Daan J Touw, PharmD, PhD, Jos G W Kosterink, PharmD, PhD, Henderik W Frijlink, PharmD, PhD, Theo Rispens, PhD, Gerard Dijkstra, MD, PhD, Marijn C Visschedijk,
doi : 10.1093/ibd/izad103
Volume 30, Issue 3, March 2024
Microbial and Metabolite Signatures of Stress Reactivity in Ulcerative Colitis Patients in Clinical Remission Predict Clinical Flare Risk
doi : 10.1093/ibd/izad185
YouTube as a Source of Information for Food, Diet-Related Items, and Advisory Comments for the Management of Inflammatory Bowel Disease
doi : 10.1093/ibd/izad076
Recommendations for Standardizing MRI-based Evaluation of Perianal Fistulizing Disease Activity in Pediatric Crohn’s Disease Clinical Trials
doi : 10.1093/ibd/izad134
Predicting Endoscopic Improvement in Ulcerative Colitis Using the Ulcerative Colitis Severity Index
doi : 10.1093/ibd/izad074
The Impact of Inflammatory Bowel Disease on Intimacy: A Multimethod Examination of Patients’ Sexual Lives and Associated Healthcare Experiences
doi : 10.1093/ibd/izad106
1-Year Comparative Effectiveness of Tofacitinib vs Ustekinumab for Patients With Ulcerative Colitis and Prior Antitumor Necrosis Factor Failure
doi : 10.1093/ibd/izad087
Bedside Intestinal Ultrasound Predicts Disease Severity and the Disease Distribution of Pediatric Patients With Inflammatory Bowel Disease: A Pilot Cross-sectional Study
doi : 10.1093/ibd/izad083
Inflammatory Bowel Disease in Appalachian Kentucky: An Investigation of Outcomes and Health Care Utilization
doi : 10.1093/ibd/izad096
Higher Ustekinumab Levels in Maintenance Therapy are Associated with Greater Mucosal Healing and Mucosal Response in Crohn’s Disease: An Experience of 2 IBD Centers
doi : 10.1093/ibd/izad073
Exclusive Enteral Nutrition Alleviates Th17-Mediated Inflammation via Eliminating Mechanical Stress–Induced Th17-Polarizing Cytokines in Crohn’s-like Colitis
doi : 10.1093/ibd/izad158
Expression of Circulating let-7e and miR-126 May Predict Clinical Remission in Patients With Crohn’s Disease Treated With Anti-TNF-α Biologics
doi : 10.1093/ibd/izad181
Relationship Between Rectal Swab and Tissue Samples in Mucosa-associated Microbiota in Patients With Inflammatory Bowel Disease
doi : 10.1093/ibd/izad179
Are the New Biologics Effective in the Management of Postoperative Crohn’s Disease?
doi : 10.1093/ibd/izad033
Significant Racial and Ethnic Disparities Exist in Health Care Utilization in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
doi : 10.1093/ibd/izad045
Brain-Gut Axis: Invasive and Noninvasive Vagus Nerve Stimulation, Limitations, and Potential Therapeutic Approaches
doi : 10.1093/ibd/izad211
Intralesional Injections of a TNF-α Inhibitor to Treat Orofacial Granulomatosis
doi : 10.1093/ibd/izae001
Inflammatory Bowel Diseases-related Disability: Risk Factors, Outcomes, and Interventions
doi : 10.1093/ibd/izad182
Correction to: Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study
doi : 10.1093/ibd/izae017
Failure Rate of Anti-Tumor Necrosis Factor α Biologics in Very Early Onset Inflammatory Bowel Disease
doi : 10.1093/ibd/izad313
Response to Letter to the Editor: “Failure Rate of Antitumor Necrosis Factor Alpha Biologics in Very Early Onset Inflammatory Bowel Disease�
doi : 10.1093/ibd/izad317
